identified to have had postoperative VTE, a 37-year-old transgender woman presenting 20 days after vaginoplasty with right thigh pain. Extensive lower extremity occlusion required endovascular thrombectomy/thrombolysis and angioplasty. No pulmonary embolus was identified. Other than estradiol therapy (injection) and surgery, no perioperative risk factors were identified.
INTRODUCTION:
Surgical site infections contribute significantly to patient morbidity and increase healthcare costs. In an attempt to lower infection rates, national guidelines have been established through the Surgical Care Improvement Project (SCIP). This protocol, developed from retrospective data, recommends administration of a single dose of antibiotics within 1 hour of surgery and discontinuation within 24 hours. Despite these guidelines, with the frequent use of prosthetic devices and surgical drains, many plastic surgeons continue to use antibiotics for durations >24 hours postoperatively. The purpose of this study was to conduct a randomized, prospective trial utilizing the SCIP recommendations verses an extended duration of antibiotic therapy, comparing infection rates leading to prosthesis loss in tissue expander-based breast reconstruction.
METHODS:
A large, single-center, prospective study was conducted from 2013 to 2018. Patients presenting for tissue expander-based breast reconstruction were randomized to receive perioperative antibiotics according to the SCIP recommendations, or an extended course of antibiotics while surgical drains remained in place. Basic demographic and patient medical information were recorded. Patients received routine postoperative follow-up. Outcomes were evaluated including tissue expander infection rates leading to expander loss, final reconstruction outcomes, and additional complications.
RESULTS:
A total of 88 tissue expander-based breast reconstruction cases qualified for inclusion in our study. Thirty-nine cases (44%) received antibiotics according to the SCIP recommendations, and 49 cases (56%) received extended antibiotic therapy. No statistically significant differences were seen regarding patient demographic information, comorbidities, or additional risk factors between the 2 groups. Infection leading to expander loss was seen in 15.4% of SCIP cases and 22.4% of extended antibiotic cases, with no statistically significant difference seen (P > 0.05). Of the patients requiring reoperation secondary to infection, 8 cases received salvage therapy with placement of antibioticimpregnated polymethylmethacrylate (4 SCIP, 4 extended antibiotics), and 9 cases underwent expander explantation (2 SCIP, 7 extended antibiotics) (P > 0.05). Final reconstruction was performed in 94.9% of SCIP cases and 91.8% in the extended antibiotic group (P > 0.05); the rate of conversion to autologous tissue reconstruction was 18.9% in the SCIP group and 28.9% in the extended antibiotic group (P > 0.05).
CONCLUSION:
Despite frequent concerns of increased infection rates with implant devices and surgical drains, this large prospective study reveals that single-dose, perioperative antibiotics are as effective in infection prevention as an extended course of antibiotics. Lessening antibiotic usage with just an intraoperative dose with help decreases healthcare costs without compromising patient outcomes.
